Literature DB >> 25001464

Ovarian cancer: TRINOVA-1, beyond VEGF inhibition.

M Teresa Villanueva.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25001464     DOI： 10.1038/nrclinonc.2014.118

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

Authors:  Bradley J Monk; Andrés Poveda; Ignace Vergote; Francesco Raspagliesi; Keiichi Fujiwara; Duk-Soo Bae; Ana Oaknin; Isabelle Ray-Coquard; Diane M Provencher; Beth Y Karlan; Catherine Lhommé; Gary Richardson; Dolores Gallardo Rincón; Robert L Coleman; Thomas J Herzog; Christian Marth; Arija Brize; Michel Fabbro; Andrés Redondo; Aristotelis Bamias; Marjan Tassoudji; Lynn Navale; Douglas J Warner; Amit M Oza
Journal:  Lancet Oncol       Date:  2014-06-17       Impact factor: 41.316
  1 in total
  1 in total

Review 1.  New ways to successfully target tumor vasculature in ovarian cancer.

Authors:  Xiaoyun Yang; Fangrong Shen; Wei Hu; Robert L Coleman; Anil K Sood
Journal:  Curr Opin Obstet Gynecol       Date:  2015-02       Impact factor: 1.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.